Aston Villa agree deal to sell women's team to owner V Sports
Villa say they have no issues regarding the Premier League's profitability and sustainability rules (PSR) and are having positive discussions with UEFA about a resolution in relation to compliance with its financial fair play (FFP) regulations.
Advertisement
V Sports is the parent company which owns Villa and was previously founded as NWSE, before being rebranded in 2021. It is jointly owned by American billionaire Wes Edens and Egyptian billionaire Nassef Sawiris, the latter of whom is Villa chairman.
V Sports also owns a 29 per cent stake in Portuguese side Vitoria S.C. and a 25 per cent stake in Spanish side Real Union. It holds partnership agreements with Egyptian Premier League club ZED FC and Vissel Kobe of the J1 League.
The Athletic reported last week that Villa were exploring the option of selling their women's team to help with PSR compliance. One source, speaking on the condition of anonymity to protect relationships, said Villa have been looking into a sale for the past 18 months, having recorded losses of £195million ($267) over the past two years — leaving them in danger of breaching PSR.
Villa's move mirrors one which fellow Premier League side Chelsea made in June 2024, when their women's team was sold to BlueCo, the company which owns the west London club, for £200m. In May, Chelsea sold an eight per cent stake in the women's team to Alexis Ohanian, founder of Reddit and husband of tennis star Serena Williams. That stake put the total value of the team at approximately £245m.
Villa finished sixth in the Women's Super League (WSL) last season and have played in the English top flight since 2020-21. The men's team also finished sixth in 2024-25 and will play in the Europa League next term as a result.
Villa reported a loss of £85.4mi for the 2023-24 season following a loss of £119.6m for 2022-23. They turned a profit of £300,000 in 2021-22 but a combined loss of more than £105mi over three seasons would constitute a PSR breach, although spending on infrastructure, youth and women's football is exempt.
()
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
11 minutes ago
- New York Times
Joao Felix completes permanent Al Nassr transfer from Chelsea
Al Nassr have completed the signing of Joao Felix from Chelsea on a permanent transfer. The Athletic reported on Sunday that the Saudi Pro League (SPL) side had agreed a deal worth €30million (£26.2m; $35.2m) upfront fee, with add-ons taking the total valuation to €50m. The 25-year-old who was the subject of interest from one large club in Portugal and others from the SPL. "I'm here to spread win together." João Félix is Nassrawi ✍️ — AlNassr FC (@AlNassrFC_EN) July 29, 2025 Felix established himself as one of Europe's most promising young players while at Benfica before becoming one of the most expensive players in history with a move to Atletico Madrid in 2019. The versatile forward joined Chelsea on loan in the second half of the 2022-23 and completed a permanent move to Stamford Bridge in the summer of 2024, scoring seven goals across 20 appearances. Felix spent the second half of 2024-25 on loan at AC Milan, said upon his departure he 'would be willing to remain' at the Serie A side beyond the loan agreement, should there be an opportunity to do so. Felix will linkup with Portugal international team-mate Cristiano Ronaldo at Al Nassr, as well as 22-time Portugal international Otavio.
Yahoo
39 minutes ago
- Yahoo
'I never once thought I needed to get out'
Jack Butland insists he never considered seeking an escape route this summer and Rangers remains the club "where I want to be". The former England goalkeeper lost his Ibrox starting spot to Liam Kelly during the final months of last term under interim boss Barry Ferguson. But Butland, 32, was give the gloves by new head coach Russell Martin for the season-opening first-leg win over Panathinaikos in Champions League qualifying last week and is determined to build on that impressive performance. "Has it been smooth sailing, my time at the club? Not for me personally, for all of us, no, it's not been quite as successful as we'd like it to have been," Butland told Sky Sports. "I never lost that, I didn't walk away from the season thinking, although some people like to try and make those stories up, that that's the end of it. "I was very determined that I will determine how my career goes here. "Obviously things can be taken out of your hands at times, but I was very adamant in the summer that regardless of what happens, what managerial changes, ownership changes, that I was going to come in and be the best version of myself and at least give myself the opportunity to have control of what happens next. "I hope I've managed to do that. I certainly feel fit and sharp and positive and looking forward to the season ahead at a club where I want to be. "I never once looked away from it and thought I need a change or I need to get out. "I need to keep my head up, stick my chest out and get on with it. That's the plan."
Yahoo
39 minutes ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
